Opinion

Podcast

A Patient-Centric Medcast on the Journey Through Moderate Plaque Psoriasis

Advanced practice providers in dermatology discuss exciting developments in the treatment landscape of plaque psoriasis. Listen to their insights into the often-challenging journey patients go on. The arrival of novel oral systemic treatment options offers opportunities to alleviate the burden of this chronic disease.

To watch the video series component of this episode, click here.

00:00 Introductions

02:10 The impact of plaque psoriasis

07:48 Absence of treatment or under treatment of plaque psoriasis

12:50 Prescribing novel systemic medications in plaque psoriasis as an advanced practice provider

15:46 Classifying moderate disease in plaque psoriasis

19:43 Getting payer approval for your patients with plaque psoriasis

23:18 Novel oral systemic treatments for plaque psoriasis

25:03 Pivotal clinical trial data on deucravacitinib

27:58 Deciding on aprimilast versus deucravacitinib for your patients with plaque psoriasis

31:53 Mechanism of action of deucravacitinib

38:13 Selecting a therapy in the evolving treatment landscape for your patient with plaque psoriasis

43:08 Educating your patients on injectables and orals systemic treatments

46:58 Summary

Related Videos
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD
2 Helpful Clinical Tips for Dermatologists, with Eingun James Song, MD
What Are Some Other Methods To Manage Skin Cancer Outside of Biopsies?
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Christopher Bunick, MD, PhD: Facts About Systemic Therapies’ Safety, Mechanism of Action
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
© 2024 MJH Life Sciences

All rights reserved.